Clinical and histologic response to single-dose treatment of moderate to severe psoriasis with an anti-CD80 monoclonal antibody

Journal of the American Academy of Dermatology

Volumn 47, Issue 5, 2002, Pages 692-700

  Gottlieb, Alice B ^a   Lebwohl, Mark ^b   Totoritis, Mark C ^c   Abdulghani, Ahsan A ^a   Shuey, Steve R ^c   Romano, Patricia ^a   Chaudhari, Umesh ^a   Allen, Roberta S ^c   Lizambri, Richard G ^c  

^a ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c BIOGEN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIGEN; CD8 ANTIGEN; GALIXIMAB; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD80; UNCLASSIFIED DRUG;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; CHILL; CLINICAL ARTICLE; DISEASE SEVERITY; DRUG HALF LIFE; FEMALE; FEVER; HEADACHE; HISTOPATHOLOGY; HUMAN; INFECTION; LYMPHOCYTE COUNT; MALE; PRIORITY JOURNAL; PSORIASIS; SINGLE DRUG DOSE; T LYMPHOCYTE ACTIVATION; VERTIGO;

EID: 0036828011     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1067/mjd.2002.124698     Document Type: Article

References (35)

1. Greaves M, Weinstein G. Treatment of psoriasis. N Engl J Med 1995;332:581-8.
2. Krueger J, Wolfe J, Nabeya R, Vallat V, Gilleaudeau P, Heftler N, et al. Successful ultraviolet B treatment of psoriasis is accompanied by a reversal of keratinocyte pathology and by selective depletion of intraepidermal T cells. J Exp Med 1995;182:2057-68.
3. Gottlieb S, Gilleaudeau P, Johnson R, Estes L, Woodworth T, Gottlieb A, et al. Response of psoriasis to a lymphocyte-selective toxin (DAB3891L-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nat Med 1995;1:442-7.
4. Valdimarsson H, Baker BS, Jonsdottir I, Fry L. Psoriasis: A disease of abnormal keratinocyte proliferation induced by T lymphocytes. Immunol Today 1986;7:256-9.
5. Gottlieb AB, Lifshitz B, Fu SM, Staiano-Coico L, Wang CY, Carter DM. Expression of HLA-DR molecules by keratinocytes, and presence of Langerhans cells in the dermal infiltrate of active psoriatic plaques. J Exp Med 1986;164:1013-28.
6. Krueger JG, Walters IB, Miyazawa M, Gilleaudeau P, Hakimi J, Light S, et al. Successful in vivo blockade of CD25 (high-affinity interleukin 2 receptor) on T cells by administration of humanized anti-Tac antibody to patients with psoriasis. J Am Acad Dermatol 2000;43:448-58.
7. Bretscher P, Cohn M. A theory of self-nonself discrimination. Science 1970;169:1042-9.
8. Bretscher PA. A two-step, two-signal model for the primary activation of precursor helper T cells. Proc Natl Acad of Sci U S A 1999;96:185-90.
9. Chambers CA, Allison JP. Costimulatory regulation of T cell funo function. Curr Opin Cell Biol 1999;11:203-10.
10. Dong H, Zhu G,Tamada K, Chen L. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med 1999;5:1365-9.
11. Wang S, Zhu G, Chapoval AI, Dong H, Tamada K, Ni J, et al. Costimulation of T cells by B7-H2, a B7-like molecule that binds ICOS. Blood 2000;96:2808-13.
12. Chapoval AI, Ni J, Lau JS, Wilcox RA, Flies DB, Liu D, et al. B7-H3: A costimulatory molecule for T cell activation and IFN-gamma production. Nat Immunol 2001;2:269-74.
13. Nickoloff BJ, Mitra RS, Lee K, Turka LA, Green J, Thompson C, et al. Discordant expression of CD28 ligands, BB-1, and B7 on keratinocytes in vitro and psoriatic cells in vivo. Am J Pathol 1993;142:1029-40.
14. Nickoloff B, Nestle F, Zheng X, Turka L. T lymphocytes in skin lesions of psoriasis and mycosis fungoides express B7-1: A ligand for CD28. Blood 1994;83:2580-6.
15. Tada Y, Nagasawa K, Ho A, Morito F, Koarada S, Ushiyama O, et al. Role of the costimulatory molecule CD28 in the development of lupus in MRL/Ipr mice. J Immunol 1999;163:3153-9.
16. Girvin AM, Dal Canto MC, Rhee L, Salomon B, Sharpe A, Blue-stone JA, et al. A critical role for B7/CD28 costimulation in experimental autoimmune encephalomyelitis: A comparative study using costimulatory molecule-deficient mice and monoclonal antibody blockade. J Immunol 2000;164:136-43.
17. Oliveira-dos-Santos AJ, Ho A, Tada Y, Lafaille JJ, Tonegawa S, Mak TW, et al. CD28 costimulation is crucial for the development of spontaneous autoimmune encephalomyelitis. J Immunol 1999;162:4490-5.
18. Mathur M, Herrmann K, Qin Y, Gulmen F, Li X, Krimins R, et al. CD28 interactions with either CD80 or CD86 are sufficient to induce allergic airway inflammation in mice. Am J Respir Cell Mol Biol 1999;21:498-509.
19. Brunet JF, Denizot F, Luciani MF, Roux-Dosseto M, Suzan M, Mattei MG, et al. A new member of the immunoglobulin superfamily-CTLA-4. Nature 1987;328:267-70.
20. Waterhouse P, Penninger J, Timms E, Wakeham A, Shahinian A, Lee K, et al. Lymphoproliferative disorders with early lethality in mice deficient in CTLA-4. Science 1995;270:985-8.
21. Ferenczi K, Burack L, Pope M, Krueger JG, Austin LM. CD69, HLA-DR and the IL-2R identify persistently activated T cells in psoriasis vulgaris lesional skin: Blood and skin comparisons by flow cytometry. J Autoimmun 2000;14:63-78.
22. Linsley P, Greene J, Brady W, Bajorath J, Ledbetter J, Peach R. Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors. Immunity 1994;1:793-801.
23. Gallon L, Chandraker A, Issazadeh S, Peach R, Linsley P, Turka L, et al. Differential effects of B7-1 blockade in the rat experimental autoimmune encephalomyelitis model. J Immunol 1997;159:4212-6.
24. Herold K, Vezys V, Koons A, Lenschow D, Thompson C, Bluestone J. CD28/B7 costimulation regulates autoimmune diabetes induced with multiple low doses of streptozotocin. J Immunol 1997;158:984-91.
25. Kuchroo V, Das M, Brown J, Ranger A, Zamvil S, Sobel R, et al. B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: Application to autoimmune disease therapy. Cell 1995;80:707-18.
26. Lenschow D, Ho S, Sattar H, Rhee L, Gray G, Nabavi N, et al. Differential effects of anti-B7-1 and anti-B7-2 monoclonal antibody treatment on the development of diabetes in the nonobese diabetic mouse. J Exp Med 1995;181:1145-55.
27. Nakajima A, Azuma M, Kodera S, Nuriya S, Terashi A, Abe M, et al. Preferential dependence of autoantibody production in murine lupus on CD86 costimulatory molecule. Eur J Immunol 1995;25:3060-9.
28. Newman R, Alberts J, Anderson D, Carner K, Heard C, Norton F, et al. "Primatization" of recombinant antibodies for immunotherapy of human diseases: A macaque/human chimeric antibody against human CD4. Biotechnology 1992;10:1455-60.
29. Abrams JR, Kelley SL, Hayes E, Kikuchi T, Brown MJ, Kang S, et al. Blockade of T lymphocyte costimulation with cytotoxic T lymphocyte-associated antigen 4-immunoglobulin (CTLA4Ig) reverses the cellular pathology of psoriatic plaques, including the activation of keratinocytes, dendritic cells, and endothelial cells. J Exp Med 2000;192:681-93.
30. Abrams J, Lebwohl M, Guzzo C, Jegasorthy B, Goldfarb M, Goffe B, et al. CTLA41g-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris. J Clin Invest 1999;103:1243-52.
31. Perkins W, Williams RE, Vestey JP, Tidman MJ, Layton AM, Cunliffe WJ, et al. A multicentre 12-week open study of a lipid-soluble folate antagonist, piritrexim in severe psoriasis. Br J Dermatol 1993;129:584-9.
32. Fredriksson T, Pettersson U. Severe psoriasis-oral therapy with a new retinoid. Dermatologica 1978;157:238-44.
33. Gottlieb A, Krueger JG, Bright R, Ling M, Lebwohl M, Kang S, et al. Effects of administration of a single dose of a humanized monoclonal antibody to CD11a on the immunobiology and clinical activity of psoriasis. J Am Acad Dermatol 2000;42:428-35.
34. Demidem A, Taylor J, Grammar S, Streilein J. T-lymphocyte-activating properties of epidermal antigen-presenting cells from normal and psoriatic skin: Evidence that psoriatic epidermal antigen-presenting cells resemble cultured normal Langerhans cells. J Invest Dermatol 1991;97:454-60.
35. Sabzevari H, Kantor J, Jaigirdar A, Tagaya Y, Naramura M, Hodge J, et al. Acquisition of CD80 (B7-1) byT cells. J Immunol 2001;166:2505-13.